세계 동물용 광견병 백신 시장 규모는 2024년 6억 1,254만 달러에서 2032년 8억 3,959만 달러에 달할 것으로 예상되며, 2025-2032년의 예측 기간 동안 연평균 4.02% 성장할 것으로 예측됩니다. 세계 시장 성장의 주요 원인은 사회적 이해의 확대, 빠르게 진행되는 전 세계 도시 통합, 정부 규제, 광견병 바이러스의 변화, 세계 여행 활동의 활성화, 소비자의 소비력 증가 등이 주요 요인으로 꼽힙니다.
여러 국가에서 질병 발생을 막기 위한 예방 조치로 반려동물의 광견병 예방접종을 의무화하고 있으며, 동시에 사람에 대한 감염 위험을 최소화하기 위해 노력하고 있습니다. 다양한 지역에서의 광견병 대책은 동물용 백신에 크게 의존하고 있으며, 개가 매개하는 인간 광견병을 막기 위한 전 세계적인 노력도 지원하고 있습니다. 의료 당국은 특히 고위험 지역에서 예방 수준을 유지하기 위해 정기적인 간격으로 부스터 백신을 접종할 것을 권장하고 있으며, 이는 전 세계 동물용 광견병 백신 시장의 성장을 가속하고 있습니다. 백신 접종 노력과 함께 대중 인식 개선 및 길 잃은 동물 통제 프로그램을 결합하는 것이 광견병 예방의 주요 방법이며, 이는 사람과 동물을 모두 보호할 수 있습니다.
예를 들어 2024년 3월 스페인 국립연구위원회(Consejo Superior de Investigaciones Cientificas)와 젠달 그룹의 공동연구로 동물에서 사람에게도 감염될 수 있는 심각한 인수공통감염병인 감염질환인 개 리슈만병에 대한 세계 최초의 DNA 백신인 Neoleish가 출시되었습니다.
세계의 동물용 광견병 백신 시장에 대해 조사 분석했으며, 시장 규모와 예측, 시장 역학, 주요 기업 개요 등의 정보를 전해드립니다.
Global rabies veterinary vaccines market is projected to witness a CAGR of 4.02% during the forecast period 2025-2032, growing from USD 612.54 million in 2024 to USD 839.59 million in 2032. Global market growth receives its main boost from public understanding expansion, along with fast-paced worldwide integration of cities, government rules, virus rabies change, rising worldwide travel activity, and increasing consumer spending power.
Multiple nations require pet rabies vaccinations as a preventive measure to stop disease outbreaks while minimizing human infection risks. Rabies control across different regions has depended heavily on veterinary vaccines, which also support global initiatives to stop dog-transmitted human rabies. The medical authorities recommend receiving booster vaccination doses at regular intervals to sustain protection levels, particularly in areas with high risk, driving the global rabies veterinary vaccines market growth. The combination of vaccination initiatives with public education efforts and stray animal control programs serves as the main method to prevent rabies, which safeguards both humans and animals.
For instance, in March 2024, a Spanish National Research Council (Consejo Superior de Investigaciones Cientificas) collaboration with Zendal group launched Neoleish, the world's first DNA vaccine against canine leishmaniasis, a serious zoonosis that can also be transmitted from animals to humans.
Growing Public Awareness Boosts Global Rabies Veterinary Vaccines Market Demand
The rising awareness concerning rabies prevention acts as the main factor that boosts the veterinary vaccine market demand. Nonprofit organizations working with governments and animal welfare groups partner with educational programs that teach pet owners and local populations about the deadly aspects of rabies and vaccination needs. Public health campaigns combine with social media outreach and veterinary initiatives to promote immediate vaccinations for all pets and stray animals, which leads to higher vaccination compliance. The implementation of mandatory vaccination policies in various countries leads people to comply with vaccination rules because they understand rabies as a zoonotic disease. The media uses both rabies outbreak reports and elimination program success stories to show how vaccines protect human lives. The partnership of health authorities with veterinarians and community groups establishes trust in vaccination, which leads to increased immunization of people. The rising awareness and knowledge about rabies lead pet owners to vaccinate their animals and enhance public support for stray animal vaccination programs. The public changes in understanding and behavior regarding rabies vaccines generate significant increases in veterinary vaccine sales, which helps drive worldwide rabies elimination efforts.
Additionally, to raise awareness among the people about the vaccination government is taking the initiative by launching programs. For instance, in September 2024, on World Rabies Day, WHO introduced a theme, 'Breaking Rabies Boundaries,' which means that One Health is not for a selected few but for everyone. This theme calls for new ways of thinking and partnership across sectors and places, centering on the need to harmonize work on human and animal health, as well as environmental health. By getting beyond boundaries, breaking down geographic, socio-economic, and educational barriers, can achieve proper vaccination, awareness, and medical care for everybody. This integrated approach is imperative to combating rabies to create a world where rabies afflict no one, human or canine.
Mandatory Vaccination Policies Fuel Market Growth
The enforcement of mandatory vaccination policies serves as an essential market expansion factor that drives the growth of rabies veterinary vaccines through their widespread use among domestic animals and livestock. Multiple countries, together with their regulatory bodies, enforce mandatory rabies vaccination of animals to stop this deadly disease from spreading among animals and humans. Such regulations generate continuous vaccine demand because domestic animal and livestock owners, together with veterinary medical facilities, must follow established legal vaccination protocols. The market experiences additional growth because public education efforts are combined with free vaccination programs. Pharmaceutical corporations dedicate funds to research and development activities, which result in new cost-effective vaccines designed for both industrialized and developing market regions. The market expands because of rising pet numbers, together with increasing worries about diseases that spread between species. The global rabies veterinary vaccine market will keep increasing due to rigorous vaccination law enforcement and increased government rabies eradication programs in Asia-Pacific and Africa, both of which are regions in which rabies is still endemic.
For instance, in March 2023, to reduce and control the rabies disease government framed the Animal Birth Control (Dogs) Rules to control the population of stray dogs. The focus of the rules is on anti-rabies vaccination of stray dogs and neutering of stray dogs as a means of population stabilization.
Dogs Dominate the Global Rabies Veterinary Vaccines Market
Dogs are the dominant sector in the market for rabies veterinary vaccines as they are the major vectors of transmission to humans. Because rabies is always lethal once symptoms have arisen, stopping transmission via canines is a priority of public health initiatives. Mass canine vaccination campaigns are recognized globally as the most efficient method of decreasing human cases of rabies and, hence, are the main driver of demand for veterinary rabies vaccines. Most countries have mandatory dog vaccination laws, especially in areas where rabies is still prevalent. The increasing population of pet dogs and rabies prevention awareness also supports the dominant market of canine vaccines. Vaccines have been developed for other animals (livestock or wildlife); however, dogs are a priority because they are the animal most likely to be in contact with humans. The eradication of rabies worldwide has emphasized dog vaccination because successful dog vaccination programs have made the domestic canine the center of the veterinary rabies vaccine market. Without a constant dog vaccination program, humans might have a greater resistance to rabies.
For instance, in June 2024, according to the World Health Organization, almost 99% of human rabies infections result from dog-transmitted virus spread. The age group consisting of children between five and fourteen years old experiences the highest number of victims.
North America holds the Largest Global Rabies Vaccines Market Size
North America holds the largest market size of rabies veterinary vaccines due to several key factors, such as the area being served by clear animal vaccination laws, especially for pets such as dogs and cats, which necessitate high demand for rabies vaccines. The veterinary healthcare dynamism in the U.S. and Canada has established government support for rabies prevention. Even more, the growth trajectory in rabies vaccination will be contingent on the increased awareness of zoonotic diseases among the pet-owning public. The presence of major pharmaceutical companies in this market draws confidence for this region, as these companies put significant investment into research and development of and distribution of rabies vaccines. The success of existing wildlife programs in both areas, especially rural areas, has increased demand for rabies vaccinations. Now, North America is in a favorable position, supported by animal health research, an advanced veterinary system, compliance rates with vaccination protocols, and government support. North America will continue to lead the rabies veterinary vaccine market for years to come.
For instance, in June 2024, MSD Animal Health, a division of Merck & Co., Inc., announced the availability of the NOBIVAC NXT Rabies portfolio, comprised of NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies in Canada in support of the company's ongoing commitment to rabies protection. The NOBIVAC NXT rabies portfolio is a new and innovative line of vaccines utilizing advanced Ribonucleic acid (RNA) particle technology to protect cats and dogs from rabies.
Impact of U.S. Tariffs on Global Rabies Veterinary Vaccines Market
In the United States, tariffs on rabies veterinary vaccines could increase costs for clinics, pet owners, and livestock producers, resulting in decreased rates of vaccination and increased public health risks. Since domestic production is limited, tariffs will cause shortages, with extra economic burdens placed on animal shelters and less affluent pet owners. It remains true that some domestic manufacturers may compete in a vacuum; however, even with domestically manufactured vaccines, global supply chain breaks may delay the availability of vaccines. If all vaccines imported into the United States cease without adequate production capacity, rabies control efforts may diminish, exposing animal and human populations to greater risks. Tariffs could impose an inefficiency on the market that will raise prices and not increase domestic output, reduce animal disease control and prevention programs, and reduce accessibility.
Key Players Landscape and Outlook
Leading companies develop new vaccines, improve existing ones, and tailor vaccines that serve animal species and geographic areas. Several key players expand their distribution networks by forming partnerships with other companies by making acquisitions or opening local subsidiaries to access emerging markets. The companies dedicate funds to modernize their manufacturing operations and facilities, which results in high-quality vaccine manufacturing. Leasing companies release fresh vaccines that deliver better effectiveness alongside various virus strain targets. Additionally, they collaborate with regulatory authorities to obtain product approvals while meeting legal standards. Community awareness programs operated by the companies deliver education about rabies prevention and explain why vaccination matters. The companies implement sustainable production and distribution methods, which show their dedication to corporate social responsibility.
In March 2024, Zoetis Inc. announced that they have purchased a 21-acre manufacturing facility in Melbourne to expand its current operations at the facility as well as develop new capabilities for the future, to develop and produce vaccines for sheep, cattle, dogs, cats, and horses. At the present time, 130 million doses of vaccines for companion animals and livestock are produced in Australia annually.
In November 2024, Boehringer Ingelheim AG (C.H. Boehringer Sohn AG & Co. KG.) launched the Eurican L4 vaccine for dogs to protect against the growing threat of leptospirosis, a severe and reemerging infectious disease.
Key Players Operating in Global Rabies
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.